Sector News

UK to pursue deals and acquisitions despite Brexit uncertainty

December 3, 2018
Life sciences

The UK pharmaceutical industry is pressing ahead with M&A activity and is “geared to weather any disruption due to Brexit”, suggest results of a recent survey by EY.

EY’s 19th Capital Confidence Barometer (CCB19), a biannual survey of more than 2,600 executives across 45 countries, has found that 67% of UK life sciences executives have a stable or positive outlook on the impact of Brexit on investment and acquisition activity.

However, globally the picture is less positive, with 51% of the surveyed executives believing that Brexit will negatively impact investments and acquisitions outside the UK and EU, as well as their ability to recruit and retain key talent.

According to the report, the global life sciences industry is on track to achieve $200 billion in deals in 2018, but the outlook appears to be more subdued as only 49% believe the sector economy is improving.

Matt Bartell, UK Life Sciences TAS leader for EY, comments: “It’s no surprise that UK execs are more confident on Brexit compared with their global counterparts.

“Clearly those in the life sciences industry have done their homework and are ahead of many others in ensuring they are prepared to weather the Brexit storm and are able to continue focusing efforts on driving growth through M&A.”

He continued: “We’re already seeing firms prepare by moving parts of their supply chain into the European Economic Area as well as stockpiling medicines to deal with any potential immediate disruption.”

This positive outlook contrasts with potential regulatory upheaval with the post-Brexit relocation of the European Medicines Agency. The move from London to Amsterdam, which will occur on January 1 and result in 30% of staff leaving, will force the agency to scale back its activities.

By Anna Smith

Source: Pharma Times

comments closed

Related News

May 26, 2024

From pharma to food: Vitafoods 2024 highlights

Life sciences

Beyond the vibrant displays and insightful discussions at Vitafoods 2024 stood the backdrop of a rapidly expanding nutraceutical market. With consumers increasingly seeking preventive healthcare solutions and natural alternatives to traditional medicine, the global nutraceutical industry has witnessed remarkable growth in recent years.

May 26, 2024

Genmab completes acquisition of ProfoundBio

Life sciences

Genmab has completed its $1.8 billion acquisition of ProfoundBio, a clinical-stage biotechnology company developing next-generation antibody-drug conjugates (ADC)s and ADC technologies for the treatment of cancers.

May 26, 2024

Merck to acquire life science company Mirus Bio

Life sciences

Merck has agreed to acquire US life sciences company Mirus Bio for $600 million (around €550 million) from Gamma Biosciences, a life sciences platform established by global investment firm KKR. Based in Madison, Wisconsin, Mirus Bio is a specialist in the development and commercialization of transfection reagents.

How can we help you?

We're easy to reach